Literature DB >> 21623955

Studies of locomotor network neuroprotection by the selective poly(ADP-ribose) polymerase-1 inhibitor PJ-34 against excitotoxic injury to the rat spinal cord in vitro.

Sara E Nasrabady1, Anujaianthi Kuzhandaivel, Andrea Nistri.   

Abstract

Delayed neuronal destruction after acute spinal injury is attributed to excitotoxicity mediated by hyperactivation of poly(ADP-ribose) polymerase-1 (PARP-1) that induces 'parthanatos', namely a non-apoptotic cell death mechanism. With an in vitro model of excitotoxicity, we have previously observed parthanatos of rat spinal cord locomotor networks to be decreased by a broad spectrum PARP-1 inhibitor. The present study investigated whether the selective PARP-1 inhibitor N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-(N,N-dimethylamino)acetamide.HCl (PJ-34) not only protected networks from kainate-evoked excitotoxicity, but also prevented loss of locomotor patterns recorded as fictive locomotion from lumbar (L) ventral roots (VRs) 24 h later. PJ-34 (60 μm) blocked PARP-1 activation and preserved dorsal, central and ventral gray matter with maintained reflex activity even after a large dose of kainate. Fictive locomotion could not, however, be restored by either electrical stimulation or bath-applied neurochemicals (N-methyl-D-aspartate plus 5-hydroxytryptamine). A low kainate concentration induced less histological damage that was widely prevented by PJ-34. Nonetheless, fictive locomotion was observed in just over 50% of preparations whose histological profile did not differ (except for the dorsal horn) from those lacking such a rhythm. Our data show that inhibition of PARP-1 could amply preserve spinal network histology after excitotoxicity, with return of locomotor patterns only when the excitotoxic stimulus was moderate. These results demonstrated divergence between histological and functional outcome, implying a narrow borderline between loss of fictive locomotion and neuronal preservation. Our data suggest that either damage of a few unidentified neurons or functional network inhibition was critical for ensuring locomotor cycles.
© 2011 The Authors. European Journal of Neuroscience © 2011 Federation of European Neuroscience Societies and Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21623955     DOI: 10.1111/j.1460-9568.2011.07714.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  6 in total

Review 1.  Organotypic Spinal Cord Culture: a Proper Platform for the Functional Screening.

Authors:  Sareh Pandamooz; Mohammad Nabiuni; Jaleel Miyan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Mol Neurobiol       Date:  2015-08-27       Impact factor: 5.590

Review 2.  Mechanism of Neuroprotection Against Experimental Spinal Cord Injury by Riluzole or Methylprednisolone.

Authors:  Cynthia Sámano; Andrea Nistri
Journal:  Neurochem Res       Date:  2017-12-30       Impact factor: 3.996

3.  Molecular Mechanisms Underlying Cell Death in Spinal Networks in Relation to Locomotor Activity After Acute Injury in vitro.

Authors:  Anujaianthi Kuzhandaivel; Andrea Nistri; Graciela L Mazzone; Miranda Mladinic
Journal:  Front Cell Neurosci       Date:  2011-06-17       Impact factor: 5.505

4.  The NAMPT inhibitor FK866 reverts the damage in spinal cord injury.

Authors:  Emanuela Esposito; Daniela Impellizzeri; Emanuela Mazzon; Gohar Fakhfouri; Reza Rahimian; Cristina Travelli; Gian Cesare Tron; Armando A Genazzani; Salvatore Cuzzocrea
Journal:  J Neuroinflammation       Date:  2012-04-10       Impact factor: 8.322

5.  Mechanisms underlying cell death in ischemia-like damage to the rat spinal cord in vitro.

Authors:  E Bianchetti; M Mladinic; A Nistri
Journal:  Cell Death Dis       Date:  2013-07-04       Impact factor: 8.469

6.  Microelectrode arrays in combination with in vitro models of spinal cord injury as tools to investigate pathological changes in network activity: facts and promises.

Authors:  Miranda Mladinic; Andrea Nistri
Journal:  Front Neuroeng       Date:  2013-03-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.